Pre-made Lemzoparlimab benchmark antibody ( Whole mAb, anti-CD47 therapeutic antibody, Anti-IAP/OA3/MER6 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lemzoparlimab biosimilar, Whole mAb, Anti-CD47 Antibody: Anti-IAP/OA3/MER6 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lemzoparlimab is a differentiated anti-CD47 monoclonal antibody designed to minimize inherent binding to normal red blood cells while preserving its strong anti-tumor activity. ... "Lemzoparlimab has already shown promising and differentiated features as a novel therapy in phase 1 studies.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-301-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Lemzoparlimab biosimilar, Whole mAb, Anti-CD47 Antibody: Anti-IAP/OA3/MER6 therapeutic antibody
INN Name	Lemzoparlimab
Target	CD47
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	na
Companies	I-Mab Biopharma
Conditions Approved	na
Conditions Active	Lymphoma;Solid tumours;Acute myeloid leukaemia;Myelodysplastic syndromes
Conditions Discontinued	na
Development Tech	na